An observational study in Post Menopausal Osteoporosis, sponsored by Procare Health Iberia S.L.. Completed at 20 sites in Spain. Open to female participants. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Procare Health Iberia S.L. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Osteoporosis, Postmenopausal with a site in Spain — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · Spain.
Among the 26 studies in Osteoporosis, Postmenopausal with a site in Spain, this one is one of 2 that started in 2025, is the only observational one, and was the 25th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 26 studies in Osteoporosis, Postmenopausal with a site in Spain is open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 50+ · Women only · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is above the median of 160 across 57 observational studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 504 across the 25 interventional studies, 230 across the 1 observational. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 26 have an industry lead sponsor. The 10 most frequent:
Procare Health Iberia S.L. is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Procare Health Iberia S.L. has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Osteoporosis, Postmenopausal with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis. The study will consist of a single visit that will coincide with one of the patient's usual follow-up visits according to standard clinical practice. During this visit, information will be collected from the patient's medical history and an interview will be conducted using 3 questionnaires to assess how and how often the patient takes the treatment, possible forgetfulness, and whether or not the patient is satisfied with their current treatment.
Women with postmenopausal osteoporosis who have been prescribed treatment with an oral bisphosphonate combined with Ca/D supplements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intergroup adherence
To evaluate intergroup adherence to the most common oral regimens used in the treatment of postmenopausal OP that combine BP and Ca/D supplements, using a 8-items Morisky Medication Adherence Scale
Time frame: Day 1
Persistence intergroup
To evaluate, intergroup, the persistence to the most common oral regimens used in the treatment of postmenopausal OP that combine BP and Ca/D supplements. It will be evaluated over time from the start of the combination of both until the first end date of administration of either one, and by the percentage of patients who continue with the combined treatment since its prescription
Time frame: Day 1
Adherence intragroup
To evaluate, intragroup, the adherence to the prescribed usual oral regimens, using a 8-items Morisky Medication Adherence Scale
Time frame: Day 1
Persistence intragroup
To evaluate, intragroup, the persistence to the prescribed usual oral regimens.
Time frame: Day 1
Factors of non-adherence
To evaluate possible determining factors of non-adherence to the prescribed usual oral regimens and their comparison between the different regimens.
Time frame: Day 1
Factors of non-persistence
To evaluate possible determining factors of non-persistence to the prescribed usual oral regimens and their comparison between different regimens.
Time frame: Day 1
Treatment satisfaction
To evaluate the patient's satisfaction with the combined treatment received using a Likert scale.
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Dec 2025, 9 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
Procare Health Iberia S.L.